DURECT, based in Cupertino, California, develops investigational therapies, including Larsucosterol for alcohol-associated hepatitis. Its FDA-approved products include POSIMIR and PERSERIS, while employing 48 staff since its 2000 IPO.
Durect (DRRX) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Durect's actual EPS was $0.24, beating the estimate of -$0.02 per share, resulting in a 1511.76% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
